Securities Purchase Agreement (Details Textual) (USD $)	1 Months Ended		6 Months Ended	12 Months Ended		1 Months Ended					6 Months Ended		6 Months Ended	1 Months Ended				1 Months Ended		1 Months Ended			1 Months Ended
	Mar. 31, 2011	May 31, 2010	Jun. 30, 2012	Dec. 31, 2011 Rate	May 24, 2010	Mar. 31, 2011 Maximum [Member]	Mar. 31, 2011 Minimum [Member]	Jun. 30, 2012 Minimum [Member]	Jun. 30, 2012 Series C-2 Warrants [Member]	Dec. 31, 2011 Series C-2 Warrants [Member]	Jun. 30, 2012 Series D-1 Warrants [Member]	Dec. 31, 2011 Series D-1 Warrants [Member]	Jun. 30, 2012 Series D-2 Warrants [Member]	May 31, 2010 Series C-1 Preferred [Member]	Jun. 30, 2012 Series C-1 Preferred [Member]	Jun. 30, 2011 Series C-1 Preferred [Member]	May 24, 2010 Series C-1 Preferred [Member]	May 31, 2010 Series C-2 Preferred [Member]	May 24, 2010 Series C-2 Preferred [Member]	May 31, 2010 Series D-1 Preferred [Member]	May 24, 2010 Series D-1 Preferred [Member]	May 24, 2010 Series D-2 Preferred [Member]	May 31, 2010 Common Stock [Member]
Securities Purchase Agreement (Textual) [Abstract]
Aggregate of common shares of company														5,134						5,134			2,897
Preferred stock, par value			$ 0.0001	$ 0.0001													$ 0.0001				$ 0.0001
Preferred stock, shares issued			5,392	5,392
Preferred stock, shares outstanding			5,043	5,043
Cumulative dividends payable			15.00%	15.00%
Preferred stock, shares authorized			11,000	11,000
Shares of Series C1 Preferred into common stock															1,200,000,000	887,000,000
Minimum preferred stock outstanding if warrants are exercised								3,000
Preferred stock par value in Series C-1 Preferred			$ 0.0001																$ 0.0001			$ 0.0001
Redeemable convertible preferred stock shares outstanding value			$ 5,560,000	$ 5,133,000
Non-cash income on increase in estimated fair value of the Embedded Derivatives			378,000
Net increase in liability due to accrual of dividends			4,000
Amount paid upon exercise of redemption rights			5,468,000	5,116,000
Total value of the embedded derivative			4,062,000	3,680,000						9,051,000		2,539,000
Warrants Revalued									9,156,000		588,000
Number of warrants series C2 to be purchased																		10,268
Non-cash other income on the decrease in the estimated fair value of the embedded derivatives			105,000								1,951,000
Percentage of preferred stock dividends payable				5.00%
Preferred stock outstanding								1,000
Carrying value of Series C-1															5,560,000
Increase in the value of series D-2 warrants													355,000
Increased number of warrants						10,646	10,268
Decrease in warrants value due to exercise											4,021
Securities Purchase Agreement (Additional Textual) [Abstract]
Percentage of investment of proceeds contributed by employee maximum		3.00%
Proceeds from issuance of derivative obligations		6,003,000
Exercise price series C2 warrants preferred		1,000
Exercise price series D1 warrants preferred		$ 1,000
Exercise Price Series D Two Warrants Preferred		$ 1,000
Additional cash payment for right to receive Series C2 Preferred after milestones	236,000
Common stock, par value					$ 0.0001
Common stock, stated price					$ 300
Proceeds from preferred stock per share					$ 1,000
Initial conversion ratio of new preferred stock to common stock				66,667
Conversion price percentage of new preferred stock			10.00%
Preferred stock, liquidation preference price per share			$ 1,000
Mandatory exercise of warrants upon achievement of the Preclinical Milestone	7,452,000
Mandatory exercise of warrants upon achievement of the Clinical milestone	$ 3,194,000
Number of share holder right to redeemed price per share			$ 1,000
Price per share of common stock discounted from the closing market prices			$ 0.06	$ 0.27